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Abstract
Background:Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 appeared in December 2019 in Wuhan, China.
Objective: To investigate the clinical manifestations including signs and symptoms,
laboratory results, and perinatal outcomes in pregnant women with COVID-19.
Materials and Methods: Scholarly databases such as PubMed via LitCovid hub,
Embase, Scopus, Web of sciences, and Google scholar were searched on April 7,
2020. Meta-analysis was performed via comprehensive meta-analysis software using
the Mantel-Haenszel method. The event rate with 95% CI was calculated for each
variable.
Results: Ten studies were selected. The pooled prevalence for fever, post-partum
fever, cough, myalgia, fatigue, dyspnea, sore throat, and diarrhea were 66.8%, 37.1%,
35%, 24.6 %, 14.9%, 14.6%, 11.5%, and 7.6%, respectively. Laboratory test results were
49.8% for lymphopenia, 47.7% for leukocytosis, 83.7% for elevated neutrophil ratio, 57%
for elevated C-reactive protein, and 71.4% for decreased lymphocyte ratio. The rate of
cesarean section for delivery in all cases was 84%. Of the newborns of the corona-
positive mothers, only one had a positive test result. Also, there was only one death
due to a decreased lymphocyte ratio.
Conclusion: Fever was the most common sign and symptom in pregnant women with
COVID-19. Among the laboratory tests, the highest amount was related to elevated
neutrophil ratio. It seems that due to the differences between pregnant women and the
general population, special measures should be considered to treat these patients.
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1. Introduction
Coronavirus Disease 2019 (COVID-19) caused
by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) appeared for the first time in
December 2019 in Wuhan, China. Following that,
the disease spread rapidly around the world to
the point where it was confirmed a pandemic
by the World Health Organization (WHO) (1, 2).
COVID-19 is an infectious disease with respiratory
symptoms almost similar to SARS (2003) and
MERS (2012) epidemics (3, 4). In some cases,
the disease can lead to a sensitive respiratory
condition, many of which require specialized
management in the intensive care unit (ICU)
(5).
Moreover, respiratory droplets along with close
contact transmission are the considerable routes
of transmission. Aerosol transmission is also
possible in a close environment when exposed
to high concentrations of aerosol for a protracted
period (6). On the other hand, touching surfaces
or objects that are touched by an infected
person can also transmit the disease (7). A
study has also shown that older age and
comorbidity play an important role in determining
the severity and clinical consequences of the
disease (8).
Because most studies have focused on
patients infected with the new coronavirus in
the general population, bounded details are
available regarding pregnancy outcomes in
women infected with COVID-19. It has caused
particular concern among pregnant women, as
both SARS-CoV and MERS-CoV viruses have
been shown to cause severe side effects in
pregnant women (9, 10). In 2004, Wong and
colleagues conducted a study on pregnant
women with SARS in Hong Kong and observed
that the pregnant women showed higher rates
of death and mortality (11). Similarly, a study
by Mertz and colleague showed that women
infected with influenza were at a higher risk
than healthy pregnant women (12). Chen and
co-authors also reported that pregnancy with
pneumonia could be associated with the risk of
cesarean delivery, preterm delivery, a decrease
in the baby’s Apgar score, weight loss at birth, etc.
(13).
It is obvious that a parturient woman has
a relatively depressed immunity or immune
suppression, and in theory, they could be more
at risk of contracting the virus. Also, confronting
the SARS-CoV-2 during pregnancy is a serious
threat to pregnant women and their fetuses
(14, 15). Therefore, it is pertinent to prevent
pregnant women from being infected during
the epidemic/pandemic period such as that
of COVID-19, a disease without an approved
treatment.
Pregnant women are at a risk of infection to
respiratory pathogens and severe pneumonia
because they are in an immunosuppressive
state and changes in physiological adaptation
during pregnancy (e.g., increased diaphragm
levels, increased oxygen consumption) can
cause hypoxia intolerance in such patients.
For instance, the outbreak of influenza in 1918
caused a total mortality of 2.6% in the population,
however in pregnant women, it was about 37%
(16). Additionally, pregnant women were also
observed to have a higher risk of complications
from the H1N1 epidemic influenza virus infection
in 2009 and were hospitalized fourfold more
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than the other patients (relative risk 4.3 95%
CI: 2.3-7.8) (17). Therefore, it is important to
study the signs and symptoms of COVID-
19 in pregnant women as understanding the
disease and its effects on newborns are very
important.
Thus, this study is aimed at investigating
the clinical manifestation including the signs
and symptoms, laboratory results, and prenatal
outcomes in pregnant women with COVID-
19.
2. Materials and Methods
This systematic review and meta-
analysis was followed by the Preferred
Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) statement
(18).
2.1. Eligibility criteria
All included studies were investigated COVID-
19 in pregnant women or during pregnancy
and were in the English language. Studies
were excluded if the researchers didn’t have
access to the full-text of the article or the
data about the outcomes were not sufficient.
Also, studies that were not peer reviewed were
excluded.
2.2. Information sources and search
Scholarly databases including PubMed via
LitCovid hub, Embase, Scopus, Web of Sciences,
and Google Scholar were searched using specific
keywords (“2019 nCoV” OR 2019nCoV OR
“2019 novel coronavirus” OR “COVID 19” OR
COVID19 OR “new coronavirus” OR “novel
coronavirus” OR “SARS CoV-2” OR (Wuhan
AND coronavirus) OR “COVID 19” OR “SARS-
CoV” OR “2019-nCoV” OR “SARS-CoV-2” AND
pregnancy OR “pregnant women”) on April
7, 2020. Our search was not limited by the
type of study or publication date but by the
studies with full-text in the English language. We
also searched the references of the included
studies for capturing potential studies in the
field. For incomplete data, the corresponding
author of the article was contacted for more
information.
2.3. Study selection
After importing the records to EndNote X7,
the duplicate records were removed and then
screened based on the title, abstract, and
full-text considering the eligibility criteria. All
stages were conducted using two independent
reviewers and the potential disagreements
were solved through consultation with a third
reviewer.
2.4. Quality appraisal
Two independent reviewers assessed the
included studies for quality issues. Because
the final studies were case-series and case-
control, the JBI checklists related to this type
of study were used. These checklists include
10 questions for case-control and case-series
studies. These questions investigate issue
regarding domain such as inclusion criteria,
reliability and validity of methods, sampling
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process, transparency in data and results,
and statistical analysis. The detail about each
question has been mentioned at the end of the
questionnaire (Supplementary 1). We scored one
for yes and zero for no in each question (19,
20).
2.5. Outcomes measures
The investigated outcomes were signs and
symptoms (cough, diarrhea, dyspnea, fatigue,
fever, myalgia, sore throat, and post-partum
fever), laboratory test results (lymphopenia,
leukocytosis, elevated neutrophil ratio,
elevated C-reactive protein, and decreased
lymphocyte ration), type of delivery (cesarean),
and perinatal outcomes (COVID-19 positive,
low birth weight, premature, complication,
and death). For all outcome variables, we
extracted the number of events and sample
size.
2.6. Data analyses
Meta-analysis was performed for the signs
and symptoms, laboratory tests, and type of
delivery using the event rate (the proportion
of the occurrence of an event in the subjects
to the total subjects under study) with CMA
(version 2) software using the Mantel-Haenszel
method. In addition, narrative synthesis was
used for reporting the results of the perinatal
outcome. The Q-value was applied to discover
between-study heterogeneity, and I2 values were
calculated to assess statistical heterogeneity.
Random-effect model was used based on
the level of heterogeneity. Based on the
Cochrane criteria, we used the random-effect
model when the heterogeneity was over
50% (21). The event rate with 95% CI was
calculated for each variable. Egger’s test and
visual inspection of the funnel plot were used
for assessing publication bias. In addition,
a meta-regression was conducted for an
association between the mean age and each
sign and symptoms, laboratory test, and type of
delivery.
3. Results
3.1. Description of search
After searching all international databases,
4,721 articles were found; after removing
the duplicate articles, 3,985 articles were
examined in terms of title and abstract, of
which 17 articles were passed to the next stage.
Finally, after reviewing the full texts of the
articles, 10 articles entered the systematic
review (22-31). In the screening stages of
studies, they were excluded for a variety of
reasons, which included unrelated topics (two
articles), unassociated population (four articles),
and duplicate study (one article). The overall
sample size of the included studies was 135
pregnant women diagnosed with COVID-19
(Figure 1).
3.2. Characteristics of included
studies
Based on the geographical location, all
included studies were performed in China.
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Table I shows the summary characteristics of the
included studies.
3.3. Quality assessment
Based on the results of the quality assessment,
seven studies were good quality and three were
average (Table II).
3.4. Heterogeneity
Based on the data analysis, a high
level of heterogeneity was not observed
in the findings. In some cases with high
heterogeneity, the random effect was used
(Table III).
3.5. Synthesis of results
3.5.1. Signs and symptoms
Various signs and symptoms have been
reported in studies. Of these, the highest was
fever with 66.8% (95% CI; 48.3-81.2). Other
reported signs and symptoms were: post-partum
fever (37.1%, 95% CI; 18.5-60.6), cough (35.5.9%,
95% CI; 23.1-50.2), myalgia (24.6%, 95% CI; 12.1-
43.5), fatigue (14.9%, 95% CI; 7-29.1), dyspnea
(14.6%, 95% CI; 9.2-22.3), sore throat (11.5%, 95%
CI; 4.8-25.1), and diarrhea (7.6%, 95% CI; 3.3-16.5)
(Figure 2, Table III).
3.5.2. Laboratory tests
Based on data analysis, lymphopenia with
49.8% (95% CI; 30.1-69.6), leukocytosis 47.7% (95%
CI; 31.6-64.2), elevated neutrophil ratio 83.7% (95%
CI; 72.3-91.0), elevated C-reactive protein 57%
(95% CI, 43.7-69.3), and decreased lymphocyte
ratio 71.4% (95% CI; 16.4-96.9) were observed in
the studies (Figure 3,Table III).
3.5.3. Type of delivery
According to the results, the rate of cesarean
section for delivery in all cases was 84% (95% CI;
74-90.7) (Figure 4, Table III).
3.5.4. Perinatal outcomes
According to the results, of the newborns of the
corona-positive mothers, only one had a positive
test result. Also, there was only one death due to
DIC (Table IV).
3.6. Results of meta-regression
According to the findings, the only factor
that could be examined in this section was the
mean age of pregnant women. Data analysis
showed that older pregnant women have a
significantly higher fever rate (Coefficient = 0.477,
p = 0.033). For the type of delivery, the higher
average age of pregnant women significantly
associated with a higher rate in cesarean delivery
(Coefficient = 0.433, p = 0.016) (Table V).
3.7. Publication bias
Visual inspection of funnel plot and Egger’s
tests did not indicate evidence of publication bias
(p = 0.127).
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Table I. Basic information about the included studies
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Table II. JBI critical appraisal checklist applied to the included studies




Liu et al., 2020-a (27) Yes Yes Yes Yes Yes No Yes N/A No Yes 7/10
Liu et al., 2020-c (28) Yes Yes Yes Yes N/A Yes Yes Yes N/A Yes 8/10
Zhu et al., 2020 (31) Yes Yes Yes Yes No Yes Yes Yes No Yes 8/10
Yu et al., 2020 (30) Yes Yes Yes Yes No No Yes Yes N/A Yes 7/10
Khan et al., 2020 (25) Yes Yes N/A Yes No Yes N/A No No Yes 5/10
Chen et al., 2020-a (13) Yes Yes N/A Yes No Yes N/A Yes No Yes 6/10
Chen et al., 2020-b (22) Yes Yes Yes Yes Yes N/A N/A Yes No Yes 7/10
Chen et al., 2020-c (14) Yes Yes Yes Yes No No Yes Yes No Yes 7/10
Case-control
Liu et al., 2020-b (26) Yes Yes Yes Yes Yes Yes N/A Yes Yes No 8/10
Li et al., 2020 (24) Yes Yes Yes Yes No Yes N/A N/A Yes No 6/10
Case series design questions:
Q1. Were there clear criteria for inclusion in the case series?
Q2. Was the condition measured in a standard, reliable way for all participants included in the case series?
Q3. Were valid methods used for identification of the condition for all participants included in the case series?
Q4. Did the case series have consecutive inclusion of participants?
Q5. Did the case series have complete inclusion of participants?
Q6. Was there clear reporting of the demographics of the participants in the study?
Q7. Was there clear reporting of the clinical information of the participants?
Q8. Were the outcomes or follow-up results of cases reported?
Q9. Was there clear reporting of the presenting site(s)/clinic(s) demographic information?
Q10. Was the statistical analysis appropriate?
Case-control design questions:
Q1. Were the groups comparable other than the presence of disease in cases of the absence of disease in controls?
Q2. Were cases and controls matched appropriately?
Q3. Were the same criteria used for the identification of cases and controls?
Q4. Was exposure measured in a standard, valid, and reliable way?
Q5. Was exposure measured in the same way for cases and controls?
Q6. Were confounding factors identified?
Q7. Were strategies to deal with confounding factors stated?
Q8. Were outcomes assessed in a standard, valid, and reliable way for cases and controls?
Q9. Was the exposure period of interest long enough to be meaningful?
Q10. Was an appropriate statistical analysis used?
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Table III. Results of heterogeneity among included studies
Variable Sub-groups #No. ofstudies Event rate (%) 95% CI Q-value Df (Q) I
2 P-value Selectedmodel
Cough 9 35.5, (23.1-50.2) 13.93 8 42.60 0.083 Random
Diarrhea 6 7.6 (3.3-16.5) 2.65 5 0.0 0.754 Random
Dyspnea 9 14.6 (9.2-22.3) 2.55 8 0.0 0.895 Random
Fatigue 3 14.9 (7-29.1) 2.79 2 28.52 0.247 Random
Fever 10 66.8 (48.3-81.2) 26.63 9 66.2 0.002 Random
Myalgia 3 24.6 (12.1-43.5) 0.59 2 0.0 0.744 Random
Sore throat 4 11.5(4.8-25.1) 1.71 3 0.0 0.633 Random
Signs and symptoms
Post-partum fever 4 37.1 (18.5-60.6) 6.01 3 60.1 0.016 Random
Lymphopenia 7 49.8 (30.1-69.6) 17.59 6 65.90 0.007 Random
Leukocytosis 4 47.7 (31.6-64.2) 4.57 3 34.38 0.206 Random
Elevated
neutrophil ratio 3 83.7 (72.3-91.0) 0.236 2 0.0 0.889 Random
Elevated
C-reactive protein 7 57 (43.7-69.3) 8.89 6 32.53 0.180 Random
Laboratory tests
Decreased
lymphocyte ratio 3 71.4 (16.4-96.9) 19.47 2 89.73 <0.001 Random
Type of delivery Cesarean 10 84 (74.0-90.7) 9.76 9 7.84 0.370 Random
NR: Not reported; CI: Confidence interval; DF (Q): Degrees of freedom (Cochran’s Q); I2: I square
Table IV. Perinatal outcomes of pregnant women with COVID-19





Liu et al., 2020-a (27) 13 0 NR 6 0 0
Liu et al., 2020-b (26) NR NR NR NR NR NR
Liu et al., 2020-c (28) 2 0 NR 0 0 0
Zhu et al., 2020 (31) 10 0 7 5 Multiple organfailure and DIC (1) 1
Yu et al., 2020 (30) 7 1 0 NR 0 0
Khan et al., 2020 (25) 3 0 0 1 0 0
Li et al., 2020 (24) 17 0 3 4 Intrauterine fetaldistress (2) 0
Chen et al., 2020-a (13) 17 0 0 0 0 0
Chen et al., 2020-b (22) 5 0 0 0 0 0
Chen et al., 2020-c (14) 9 0 2 4 0 0
NR: Not reported
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Table V. Result of meta-regression
Variable Sub-groups Mean age
Coefficient SE P-value
Cough 0.192 0.207 0.354
Diarrhea 0.103 0.392 0.792
Dyspnea -0.110 0.236 0.640
Fatigue 0.676 0.405 0.095
Fever 0.477 0.223 0.033
Myalgia 0.0 0.322 0.999
Sore throat -0.117 0.520 0.821
Signs and symptoms
Post-partum fever -0.001 0.192 0.995
Lymphopenia 0.309 0.252 0.220
Leukocytosis 0.092 0.324 0.775
Elevated neutrophil ratio 0.141 0.443 0.749
Elevated C-reactive protein 0.057 0.231 0.802
Laboratory tests
Decreased lymphocyte ratio -0.649 0.431 0.131









Records identified through database 









 Additional records identified through 
other sources (n = 12) 
Records after duplicates removed  
(n = 3985) 
Records screened  
(n = 3985) 
Records excluded based on eligibility 









Full-text articles assessed for 







Studies included in qualitative 
synthesis (n = 10) 
Studies included in quantitative 
synthesis (meta-analysis) (n = 10) 
Excluded articles with reasons (n = 7) 
Incomplete data = 4 
Inconsistent with the purpose of the 
review = 3 
Figure 1. Study selection flow diagram.
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Figure 2. The forest plot presenting event rate and 95% CI for the signs and symptoms in pregnant women with COVID-19; (A)
cough, (B) diarrhea, (C) dyspnea, (D) fatigue, (E) fever, (F) myalgia, (G) post-partum fever, and (H) sore throat.
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Figure 3. The forest plot presenting event rate and 95% CI for the laboratory tests in pregnant women with COVID-19; (A)
lymphopenia, (B) leukocytosis, (C) elevated neutrophil ratio, (D) elevated C-reactive protein, and (E) and decreased lymphocyte
ration.
Figure 4. The forest plot presenting event rate and 95% CI for the type of delivery in pregnant women with COVID-19.
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4. Discussion
A total of 10 articles were reviewed in this study,
which analyzed 135 pregnant women, all of whom
were in the third trimester of pregnancy (22-31).
These summary findings help healthcare workers
better manage pregnant women with COVID-19,
which could potentially reduce the side effects for
women as well as their newborns.
The common clinical manifestations of
pregnant women with COVID-19 include fever and
cough, and the less common symptoms are sore
throat and diarrhea. Postpartum fever is also more
common in women after childbirth. However, the
rate of fever in our study was lower than that of
Guan and colleagues’, who studied the symptoms
of non-pregnant coronary artery disease and
reported an 87.9% rate of fever. However, similar
to our study, in their study, diarrhea was the least
common (32).
In terms of laboratory demonstrations, elevated
neutrophil ratio and decreased lymphocyte ratio
are common. On the other hand, the prevalence
of CRP elevated in our study was 57%. However,
in Zhang and co-authors’ study, this prevalence
in a group of people with non-severe and severe
patients was 88.9% and 96.4%, respectively (33).
This indicates a more pronounced inflammation
in patients with more severe conditions and given
that pregnant women in this study were not in
severe disease conditions, a lower percentage
of increased CRP prevalence is justified. On the
other hand, in Rodriguez-Morales co-workers
study, the increased CRP prevalence was
58.3%, which is similar to our study (8). These
differences in numbers can be explained due
to the severity of the disease, and on the other
hand, a more comprehensive examination is
needed.
Lymphopenia and leukocytosis were less
common in our study. However, in the study of
Zhang and colleagues and Wang and colleague ,
which was performed on patients with COVID-19
(normal population), lymphopenia was the most
common laboratory symptom and was 75.4% and
70.3%, respectively (33, 34). However, it should
be noted that these numbers are a decrease in
absolute lymphocyte count.
In our study, the majority of pregnancies ended
up with cesarean section, which is much higher
than the WHO’s recommendation for vaginal
route delivery (35), which can be determined by
a gynecologist to prevent maternal respiratory
distress during pregnancy.
In the current study, which examined 135
pregnant womenwith COVID-19 pneumonia, none
of the patients with severe or dead pneumonia
were infected with COVID-19 infection. Although
SARS-CoV-2 has a common sequence with SARS
of up to 85%, we need to be aware of the
possibility that the course of the disease and the
prognosis of this disease can follow the same
SARS process in pregnant women (36, 37).
The current study does have some limitations.
First, all patients registered in the included articles
were in the third trimester of pregnancy, and the
effect of the virus infection on the fetus in the
first or second trimester was unknown. Second,
due to the short duration of the outbreak, the
long-term consequences of the disease on infants
have not been possible and more studies are
needed. Third, the low number of samples of
articles included is another limitation of the work.
Fourth, all included studies were from China.
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5. Conclusion
In conclusion, pregnant women with COVID-
19 pneumonia had diverse symptoms; however,
fever and cough were the main clinical symptoms
in those women. Although one infant was born
with COVID-19 in the included studies, there was
little evidence that COVID-19 was transmitted from
mother to infant in late pregnancy. Therefore,
the study of long-term outcomes on mother and
child, as well as the vertical transfer of mother to
child in second-trimester pregnancies and the first
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